天臣医疗(688013) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥54,207,665.88, a decrease of 12.76% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥6,522,312.23, down 48.52% year-on-year[5]. - The basic earnings per share decreased by 50.00% to ¥0.08, while diluted earnings per share fell by 53.33% to ¥0.07[6]. - The company reported a decrease of 53.80% in net profit after deducting non-recurring gains and losses, totaling ¥4,767,083.28[5]. - Net profit for the third quarter of 2023 was ¥33,111,864.38, compared to ¥31,792,137.04 in the same quarter of 2022, representing a growth of 4.1%[25]. - The company's net profit for the first three quarters of 2023 was ¥33,617,864.49, down from ¥42,582,383.70 in the previous year, representing a decline of approximately 21.1%[34]. - In Q3 2023, the total profit amounted to ¥34,098,984.89, a decrease of 22.3% compared to ¥43,912,061.43 in Q3 2022[35]. - The net profit for Q3 2023 was ¥31,313,861.85, down 20.0% from ¥39,112,290.17 in the same period last year[35]. - The total comprehensive income for Q3 2023 was ¥31,313,861.85, reflecting a decrease of 20.0% compared to ¥39,112,290.17 in Q3 2022[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥587,326,520.91, an increase of 8.07% from the end of the previous year[6]. - The company's total assets amounted to CNY 587.33 million, an increase from CNY 543.46 million at the end of 2022[18]. - The company reported a total liability of ¥35,290,061.81 as of the end of the third quarter of 2023, slightly up from ¥35,044,738.21 at the end of the same quarter in 2022[20]. - The company's total liabilities decreased to ¥32,516,775.43 as of September 30, 2023, from ¥33,864,975.67 at the end of 2022, showing a reduction of approximately 4.0%[33]. - The total equity of the company increased to ¥571,970,798.61 as of September 30, 2023, compared to ¥530,084,185.30 at the end of 2022, reflecting a growth of approximately 7.9%[34]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥49,187,863.86, up 8.50%[5]. - The net cash flow from operating activities for the first three quarters of 2023 was ¥49,187,863.86, an increase from ¥45,334,771.43 in the same period of 2022[28]. - The net cash flow from operating activities in Q3 2023 was ¥49,976,227.27, compared to ¥47,750,783.45 in Q3 2022, reflecting a growth of 2.6%[38]. - Operating cash flow for the first nine months of 2023 was ¥198,609,720.14, an increase of 6.9% from ¥185,792,724.95 in the first nine months of 2022[37]. - The company reported a net cash flow from investing activities of ¥98,285,658.79 in Q3 2023, a decrease of 30.0% from ¥140,388,860.64 in Q3 2022[38]. - The cash flow from investing activities generated a net cash inflow of ¥96,942,057.64 in the third quarter of 2023[29]. - Total cash inflow from financing activities in Q3 2023 was ¥15,770,437.75, down 59.9% from ¥39,334,760.00 in Q3 2022[38]. - The company experienced a net cash outflow from financing activities of ¥4,340,405.80 in Q3 2023, an improvement from a net outflow of ¥35,786,686.83 in Q3 2022[38]. Research and Development - Research and development expenses totaled ¥7,981,487.21, representing 14.72% of revenue, an increase of 0.85 percentage points[6]. - Research and development expenses for the first three quarters of 2023 were ¥24,686,254.99, slightly down from ¥25,082,845.75 in the same period of 2022[24]. - The company has established a partnership with B.Braun to transfer over 120 minimally invasive surgical patents by 2024, enhancing its technological leadership in the field[15]. - The company is actively developing products for preoperative screening and postoperative recovery to improve patient quality of life[15]. - The company aims to integrate services across preoperative, intraoperative, and postoperative phases to enhance hospital efficiency and economic benefits[15]. Shareholder Information - The total number of shareholders at the end of the reporting period was 5,650, with the top two shareholders holding a combined 51.64% of shares[12].